UPDATE: Truist Securities Upgrades NextCure Inc. (NXTC) to Buy on Better Comeback Plan

Truist Securities analyst Asthika Goonewardene upgraded NextCure Inc. (NASDAQ: NXTC) from Hold to Buy with a price target of $19 (from $13).

The analyst commented, "Updates from NXTC's R&D day were very constructive in our view, and in totality, it gives us what we need to be positive on NC318 again. We believe NC318 will be active in a subset of patients across 3 tumor types - the key one being NSCLC. While the addressable market for NC318 may be smaller than what we originally forecasted, we see paths to pivotal trials (re)emerging in the next 9-15 months. Further, pipeline assets NC410 (LAIR-1) and debutant NC762 (B7-H4) have initial data in 4Q21 and mid-22, respectively, and are essentially free money (not in our valuation)."

For an analyst ratings summary and ratings history on NextCure Inc. click here. For more ratings news on NextCure Inc. click here.

Shares of NextCure Inc. closed at $11.39 yesterday.

You May Also Be Interested In

• FinecoBank (FBK:IM) PT Raised to EUR15.60 at Goldman Sachs
• Macquarie Upgrades Nanya Technology Corp (2408:TT) to Outperform
• Standard Life Aberdeen Plc. (SLA:LN) (SLFPY) PT Raised to GBP3.76 at Goldman Sachs